禽痘病毒载体 ALVAC 与基于牛痘病毒的载体 MVA 和 NYVAC 相比，在恒河猴中诱导出不同的细胞因子反应。
The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys.
机构信息
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
出版信息
J Virol. 2014 Feb;88(3):1809-14. doi: 10.1128/JVI.02386-13. Epub 2013 Nov 20.
Abstract
Despite the growing use of poxvirus vectors as vaccine candidates for multiple pathogens and cancers, their innate stimulatory properties remain poorly characterized. Here we show that the canarypox virus-based vector ALVAC induced distinct systemic proinflammatory and antiviral cytokine and chemokine levels following the vaccination of rhesus monkeys compared to the vaccinia virus-based vectors MVA and NYVAC. These data suggest that there are substantial biological differences among leading poxvirus vaccine vectors that may influence resultant adaptive immune responses following vaccination.
摘要
尽管痘病毒载体作为多种病原体和癌症的疫苗候选物的使用日益增加，但它们的固有刺激特性仍未得到很好的描述。在这里，我们表明与基于牛痘病毒的载体 MVA 和 NYVAC 相比，基于金丝雀痘病毒的载体 ALVAC 在恒河猴接种后诱导了不同的全身性促炎和抗病毒细胞因子和趋化因子水平。这些数据表明，领先的痘病毒疫苗载体之间存在着实质性的生物学差异，这可能会影响接种后的适应性免疫反应。
相似文献
1
The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys.禽痘病毒载体 ALVAC 与基于牛痘病毒的载体 MVA 和 NYVAC 相比，在恒河猴中诱导出不同的细胞因子反应。
J Virol. 2014 Feb;88(3):1809-14. doi: 10.1128/JVI.02386-13. Epub 2013 Nov 20.
2
Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.缺失编码 IRF3 抑制剂的牛痘病毒 N2L 基因可提高表达 HIV-1 抗原的改良安卡拉牛痘病毒的免疫原性。
J Virol. 2014 Mar;88(6):3392-410. doi: 10.1128/JVI.02723-13. Epub 2014 Jan 3.
3
Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.通过基因互补策略扩大基于安卡拉痘苗病毒的改良疫苗载体的种类。
PLoS One. 2009;4(5):e5445. doi: 10.1371/journal.pone.0005445. Epub 2009 May 6.
4
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.痘病毒NYVAC和ALVAC载体在非人灵长类动物中与Env蛋白进行初免-加强联合免疫时表达相同HIV-1 C亚型免疫原的头对头比较。
J Virol. 2015 Aug;89(16):8525-39. doi: 10.1128/JVI.01265-15. Epub 2015 Jun 3.
5
Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.复制型 NYVAC-KC 比非复制型 NYVAC 更能提高恒河猴对 HIV-1 抗原的免疫原性。
J Virol. 2019 Jan 17;93(3). doi: 10.1128/JVI.01513-18. Print 2019 Feb 1.
6
Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.在痘病毒和蛋白加强之前，用一种有效的 HIV-1 DNA 疫苗进行预刺激会影响免疫反应的质量。
J Virol. 2019 Jan 17;93(3). doi: 10.1128/JVI.01529-18. Print 2019 Feb 1.
7
Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.表达猿猴免疫缺陷病毒（SIV）表面糖蛋白 gp120 的重组改良安卡拉痘苗病毒可引发猕猴对 SIV 感染的快速中和抗体反应。
J Virol. 2000 Mar;74(6):2960-5. doi: 10.1128/jvi.74.6.2960-2965.2000.
8
Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors.金丝雀痘病毒和安卡拉改良牛痘病毒-人类免疫缺陷病毒疫苗载体抗原产生及诱导细胞凋亡的直接比较
J Virol. 2007 Jul;81(13):7022-33. doi: 10.1128/JVI.02654-06. Epub 2007 Apr 4.
9
Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques.ALVAC-Simian Immunodeficiency Virus 载体表达的 CD40L 可消除猕猴的 T 细胞反应。
J Virol. 2020 Feb 28;94(6). doi: 10.1128/JVI.01933-19.
10
Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys.重组金丝雀痘病毒疫苗在恒河猴体内引发针对猿猴免疫缺陷病毒显性和隐性表位的细胞毒性T淋巴细胞。
J Immunol. 2002 Feb 15;168(4):1847-53. doi: 10.4049/jimmunol.168.4.1847.
引用本文的文献
1
BCG immunization mitigates SARS-CoV-2 replication in macaques via monocyte efferocytosis and neutrophil recruitment in lungs.卡介苗免疫通过单核细胞胞葬作用和肺部中性粒细胞募集减轻猕猴体内的新冠病毒复制。
JCI Insight. 2025 Aug 8;10(15). doi: 10.1172/jci.insight.194633.
2
Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.探索临床前和临床环境中的 HIV 疫苗进展：从历史到未来展望。
Viruses. 2024 Feb 27;16(3):368. doi: 10.3390/v16030368.
3
Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.病毒载体递送免疫原可集中 HIV-1 抗体特异性，并增加循环抗体回忆反应的持久性。
PLoS Pathog. 2023 May 31;19(5):e1011359. doi: 10.1371/journal.ppat.1011359. eCollection 2023 May.
4
HIV vaccine candidate efficacy in female macaques mediated by cAMP-dependent efferocytosis and V2-specific ADCC.HIV 候选疫苗在雌性猕猴中的功效由 cAMP 依赖性胞吐作用和 V2 特异性 ADCC 介导。
Nat Commun. 2023 Feb 2;14(1):575. doi: 10.1038/s41467-023-36109-8.
5
Ex Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates.非人灵长类动物接种ALVAC和AIDSVAX后黏膜反应的体外评估
Vaccines (Basel). 2022 Jan 25;10(2):187. doi: 10.3390/vaccines10020187.
6
Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials.序列和载体形状在 HIV 疫苗试验中诱导抗体效应功能。
PLoS Pathog. 2021 Nov 29;17(11):e1010016. doi: 10.1371/journal.ppat.1010016. eCollection 2021 Nov.
7
Early Pro-Inflammatory Signal and T-Cell Activation Associate With Vaccine-Induced Anti-Vaccinia Protective Neutralizing Antibodies.早期促炎信号和 T 细胞激活与疫苗诱导的抗牛痘保护性中和抗体相关。
Front Immunol. 2021 Oct 11;12:737487. doi: 10.3389/fimmu.2021.737487. eCollection 2021.
8
Advancements in the Growth and Construction of Recombinant Lumpy Skin Disease Virus (LSDV) for Use as a Vaccine Vector.用作疫苗载体的重组牛结节性皮肤病病毒（LSDV）生长与构建的进展
Vaccines (Basel). 2021 Oct 4;9(10):1131. doi: 10.3390/vaccines9101131.
9
Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk.先天免疫特征与部分有效 HIV 疫苗相关，可预测 HIV-1 感染风险的相关因素。
PLoS Pathog. 2021 Mar 15;17(3):e1009363. doi: 10.1371/journal.ppat.1009363. eCollection 2021 Mar.
10
Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats.用于应对人畜共患病和新出现的公共卫生威胁的病毒载体疫苗的开发与应用。
Vaccines (Basel). 2020 Nov 13;8(4):680. doi: 10.3390/vaccines8040680.
本文引用的文献
1
Primary human leukocyte subsets differentially express vaccinia virus receptors enriched in lipid rafts.原代人白细胞亚群差异表达富含脂筏的牛痘病毒受体。
J Virol. 2013 Aug;87(16):9301-12. doi: 10.1128/JVI.01545-13. Epub 2013 Jun 19.
2
Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys.接种腺病毒血清型 35、26 和 48 比接种血清型 5 能在恒河猴中引起更高水平的先天细胞因子反应。
J Virol. 2012 Sep;86(18):9590-8. doi: 10.1128/JVI.00740-12. Epub 2012 Jul 11.
3
Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.系统分析 MVA-C 诱导的免疫反应揭示了其作为针对 C 型 HIV/AIDS 的候选疫苗的重要性。
PLoS One. 2012;7(4):e35485. doi: 10.1371/journal.pone.0035485. Epub 2012 Apr 19.
4
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.HIV-1 疫苗功效试验的免疫相关性分析。
N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.
5
Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice.去除阻断Ⅰ型和Ⅱ型干扰素通路的痘苗病毒基因可增强 HIV/AIDS 候选疫苗 NYVAC-C 在小鼠中的适应性和记忆应答。
J Virol. 2012 May;86(9):5026-38. doi: 10.1128/JVI.06684-11. Epub 2012 Mar 14.
6
Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein.通过删除编码白细胞介素-18 结合蛋白的病毒基因来提高 MVA 疫苗的潜力。
PLoS One. 2012;7(2):e32220. doi: 10.1371/journal.pone.0032220. Epub 2012 Feb 22.
7
A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.候选艾滋病毒/艾滋病疫苗（MVA-B）缺乏牛痘病毒基因 C6L 可增强记忆 HIV-1 特异性 T 细胞应答。
PLoS One. 2011;6(8):e24244. doi: 10.1371/journal.pone.0024244. Epub 2011 Aug 31.
8
Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.牛痘病毒：预防天花的疫苗和对抗传染病与肿瘤的载体。
Expert Rev Vaccines. 2011 Aug;10(8):1221-40. doi: 10.1586/erv.11.79.
9
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors.通过表达 HIV-1 蛋白的基因修饰 NYVAC 载体增强固有和适应性免疫刺激。
PLoS One. 2011 Feb 15;6(2):e16819. doi: 10.1371/journal.pone.0016819.
10
Canarypox and fowlpox viruses as recombinant vaccine vectors: a biological and immunological comparison.金丝雀痘病毒和禽痘病毒作为重组疫苗载体：生物学和免疫学比较。
Antiviral Res. 2010 Oct;88(1):53-63. doi: 10.1016/j.antiviral.2010.07.005. Epub 2010 Jul 17.
Zotero 插件